Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus
A legfontosabb adatok
- Ki végzi
- Azalea Vision
- Hol
- Belgium és Hollandia2 helyszín, 2 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 16 fő, tervezett
- Kezdés
- 2026. szept. 28.
- Várható befejezés
- 2027. márc. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- NOA lens type 1
- NOA lens type 2
- A regiszteradat frissítve
- 2026. október 13.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with keratoconus or presbyopia in both eyes. They will test a custom scleral contact lens with a small central opening.
- Életkor
- 18 years or older.
- Nem
- All sexes can join.
- A betegség stádiuma
- Both eyes must have one of these. Group A: keratoconus (a cone-shaped cornea) without presbyopia. Group B: presbyopia (age-related trouble focusing up close) with otherwise normal distance sight (+-0.5 D) and no corneal irregularities. The cornea must be stable, as judged by the study doctor.
- Korábbi kezelés
- No recent cross linking, and no current or recently removed corneal stitches. You must be willing to stop wearing contact lenses for at least 48 hours before every visit. No hybrid or corneal RGP lenses in the 3 months before the trial. No contact lens refitting in the month before screening.
A részvétel fő kizáró okai
- Active eye infection, inflammation or allergic eye disease.
- Glaucoma, cataract, or scarring or clouding in the center of the cornea.
- Having no natural lens or an artificial lens in the eye.
- Severe dry eye or eye surface disease, or needing eye drops every 2hrs.
- Pregnant or breastfeeding women.
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18y at time of informed consent
- Provide written Informed Consent
- Being diagnosed in both eyes with:
- Keratoconus, without having presbyopia (Group A) OR: Emmetropic (+-0.5 D) presbyopia, without having corneal irregularities (Group B)
- Cornea considered to be clinically stable at the discretion of the investigator (e.g. no recent cross linking performed, no current corneal sutures, no corneal sutures recently removed)
- Willing to remove current contact lenses (any type) in both eyes for a minimum of 48 hours prior to every study visit
- Able to read Dutch
Ki nem vehet részt
- Use of fluorescein in the eye, within 12 hours prior to the PentacamAXL Wave scan
- Contact lens refitting within one month prior to the screening PentacamAXL Wave scan (or planned refitting throughout the study), as this can significantly impact the corneal or scleral surface
- Use of hybrid contact lenses or corneal RGP contact lenses within 3 months prior to (or planned use during) study participation
- Having worn contact lenses (any type) within 48 hours prior to performing the screening Pentacam AXL Wave scan at visit 1
- Active ocular infection or inflammation, including infectious keratitis, infectious conjunctivitis or blepharitis with discharge
- Severe ocular surface disease that prevents safe lens application, stable wear, or lens removal
- Known hypersensitivity or allergy to the lens material or approved cleaning, disinfecting or filling solutions
- Active allergic eye disease, including active papillary or follicular conjunctivitis
- Systemic conditions known to impair corneal healing, such as uncontrolled autoimmune disease
- History of other known ocular pathologies that might influence the measured endpoints of the study, at the discretion of the investigator
- History of low corneal endothelial cell count (< 1500 cells/mm2) or endothelial pathologies, at the discretion of the investigator
- Medical history (of ocular pathologies) that might lead to incomplete/incorrect eye surface scan OR wavefront aberrometry, at the discretion of the investigator
- Clinically significant acute non-infectious ocular surface abnormality, including active corneal abrasion, recent ocular surface trauma
- Severe corneal hypoesthesia or neurotrophic keratopathy which would impair perception of pain, foreign body sensation or delay symptom reporting
- Glaucoma
- Central opacity and/or central corneal scarring and/or cataract
- Aphakic and pseudophakic
- Severe meibomian gland dysfunction, at the discretion of the investigator
- Known vitreoretinal pathologies, at the discretion of the investigator
- Subjects needing eye drops every 2hrs
- Pregnant or breastfeeding woman
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this clinical study is to evaluate the effectiveness of the NOA lens, a custom-made scleral contact lens developed by Azalea Vision BV, in improving visual quality for individuals with keratoconus and presbyopia.
A teljes eredeti leírásKevesebb
This clinical study investigates a new lens design featuring a specific central aperture (opening) intended to enhance image quality by increasing depth of focus and reducing optical aberrations. The NOA lens serves as a functional prototype for future "smart lens" technology, specifically the ALMA Smart Lens. The study aims to determine if this specialized lens provides a solution for patients whose visual needs are not fully met by conventional glasses or contact lenses.
The investigation will compare a standard refractive scleral lens (Type 1) against the aperture-integrated lens (Type 2) to validate the "pinhole effect" in improving vision and reducing higher-order aberrations.
A vizsgálat 2 csoportja
- KeratoconusA vizsgált kezelés
Keratoconus, without having presbyopia
Kezelés: NOA lens type 1 és NOA lens type 2
- PresbyopiaA vizsgált kezelés
Emmetropic (+-0.5 D) presbyopia, without having corneal irregularities
Kezelés: NOA lens type 1 és NOA lens type 2
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. október 13.